atenolol has been researched along with Hypertrophy in 5 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Hypertrophy: General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "normalization of blood pressure and membrane oxidant status together with prevention of hypertrophy and normalization of the augmented expression of AM, IMD and their receptor components in NO-deficient cardiomyocytes by atenolol / nifedipine supports involvement of both pressure loading and ischemic insult in stimulating cardiomyocyte hypertrophy and induction of these counter-regulatory peptides and their receptor components." | 7.74 | Influence of atenolol and nifedipine on nitric-oxide deficient cardiomyocyte hypertrophy and expression of the cardio-endocrine peptide intermedin and its receptor components. ( Bell, D; Devine, AB; McDermott, BJ; Zhao, YY, 2008) |
| "normalization of blood pressure and membrane oxidant status together with prevention of hypertrophy and normalization of the augmented expression of AM, IMD and their receptor components in NO-deficient cardiomyocytes by atenolol / nifedipine supports involvement of both pressure loading and ischemic insult in stimulating cardiomyocyte hypertrophy and induction of these counter-regulatory peptides and their receptor components." | 3.74 | Influence of atenolol and nifedipine on nitric-oxide deficient cardiomyocyte hypertrophy and expression of the cardio-endocrine peptide intermedin and its receptor components. ( Bell, D; Devine, AB; McDermott, BJ; Zhao, YY, 2008) |
| "Dobutamine was also found to be clearly stronger than salbutamol as an inducer of polypeptides C-G." | 1.31 | Cell-enlargement-related polypeptides are induced via beta(1)-adrenoceptors in mouse parotids. ( Alliende, C; González, MJ; López Solís, RO; Peña y Lillo, S, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aunapuu, M | 1 |
| Pechter, U | 1 |
| Arend, A | 1 |
| Suuroja, T | 1 |
| Ots, M | 1 |
| Bell, D | 1 |
| Zhao, YY | 1 |
| Devine, AB | 1 |
| McDermott, BJ | 1 |
| Schiffrin, EL | 1 |
| Deng, LY | 1 |
| González, MJ | 1 |
| Peña y Lillo, S | 1 |
| Alliende, C | 1 |
| López Solís, RO | 1 |
| Shantz, LM | 1 |
| Feith, DJ | 1 |
| Pegg, AE | 1 |
1 trial available for atenolol and Hypertrophy
| Article | Year |
|---|---|
Structure and function of resistance arteries of hypertensive patients treated with a beta-blocker or a calcium channel antagonist.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Arteries; Atenolol; Calcium Channel Blockers; Female; Huma | 1996 |
4 other studies available for atenolol and Hypertrophy
| Article | Year |
|---|---|
Ultrastructural changes in the remnant kidney (after 5/6 nephrectomy) glomerulus after losartan and atenolol treatment.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atenolol; Ba | 2003 |
Influence of atenolol and nifedipine on nitric-oxide deficient cardiomyocyte hypertrophy and expression of the cardio-endocrine peptide intermedin and its receptor components.
Topics: Adrenomedullin; Animals; Atenolol; Atrial Natriuretic Factor; Blood Pressure; Endothelin-1; Gene Exp | 2008 |
Cell-enlargement-related polypeptides are induced via beta(1)-adrenoceptors in mouse parotids.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Albuterol; Animals; Atenolol; Cell Size; Dobu | 2000 |
Targeted overexpression of ornithine decarboxylase enhances beta-adrenergic agonist-induced cardiac hypertrophy.
Topics: Adrenergic beta-Agonists; Animals; Atenolol; Blotting, Southern; Cadaverine; Cardiomegaly; Hypertrop | 2001 |